Molecules 1 and 7 possessed a highly potent CSC inhibitory activity to MDA-MB-231 breast cancer cell line and displayed similar effects in reducing the percentage of CD44+/CD24− breast CSC subpopulation at 1 μM. This evidence concerns the gene CD44 and breast cancer.